KENILWORTH, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Schering-Plough (NYSE: SGP), maker of the top-selling allergy medicine, CLARITIN, announces its second Sprint Cup racing season as a sponsor of NASCAR star and long-time allergy sufferer Carl Edwards. Edwards, who takes non-drowsy CLARITIN to treat his allergy symptoms, will drive the No. 99 CLARITIN Ford Fusion during the April NASCAR Sprint Cup race at Talladega Superspeedway, NASCAR's most competitive track.
Advertisement
(Photo: http://www.newscom.com/cgi-bin/prnh/20090212/NY69974 )
"As a driver who races at speeds up to 180 miles an hour, I can't risk taking an allergy medicine that might make me drowsy," said Edwards. "I've continued my partnership with CLARITIN because it works hard to relieve my worst allergy symptoms without drowsiness, so I can think and react fast."
Advertisement
Last year, Edwards was runner-up in both the 2008 NASCAR Sprint Cup Series and NASCAR Nationwide Series point standings. He also was the voice of the CLARITIN Clear To Drive(SM) campaign which emphasizes the importance of reading medicine labels to check for warnings about drowsiness before getting behind the wheel of a car.
"We are thrilled to continue our relationship with Carl Edwards, and we're proud of his accomplishments," said TJ Higgins, Group Vice President, Marketing, Schering-Plough Consumer HealthCare. "Carl has been instrumental in letting consumers know that CLARITIN effectively relieves both indoor and outdoor allergy symptoms without drowsiness and is safe to take when driving."
For more information on allergies and treatments, visit www.CLARITIN.com.
About CLARITIN(R)
All CLARITIN(R) brand products are available without a prescription, including: CLARITIN(R) Tablets, a once-daily, full prescription strength, non-drowsy formulation; CLARITIN(R) RediTabs(R) Tablets, a novel once-daily formulation in a quickly dissolving tablet for ages 6 and older; CLARITIN(R) Liqui-Gels(R), a once-daily formulation in an easy-to-swallow liquid-filled capsule; CLARITIN-D(R) 24-hour and 12-hour Extended Release Tablets, with the decongestant pseudoephedrine, now located behind the counter; CHILDREN'S CLARITIN(R) Syrup, a liquid formulation for children ages 2 and older in grape and fruit flavors; and CHILDREN'S CLARITIN(R) Grape Chewables, a chewable tablet for children ages 2 and older.
CLARITIN(R) is the No. 1 physician-recommended and pediatrician-recommended non-drowsy over-the-counter allergy brand. The CLARITIN(R) Rx-to-OTC switch in 2002 was the largest switch ever--and the first and only for a non-drowsy antihistamine. For more information on allergies and treatment, visit www.CLARITIN.com.
About Schering-Plough
Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to potential market for CLARITIN. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the third quarter 2008 10-Q, filed October 29, 2008.
SOURCE Schering-Plough
